Lymphoproliferative disorder of the airway of an adolescent without immunodeficiency

被引:1
作者
Boesch, RP [1 ]
Daines, M
Kaul, A
Cotton, R
Amin, R
机构
[1] Childrens Hosp, Med Ctr, Div Pediat Pulm Med, Cincinnati, OH 45229 USA
[2] Childrens Hosp, Med Ctr, Div Pediat Allergy & Immunol, Cincinnati, OH 45229 USA
[3] Childrens Hosp, Med Ctr, Div Pediat Gastroenterol, Cincinnati, OH 45229 USA
[4] Childrens Hosp, Med Ctr, Div Pediat Otolaryngol, Cincinnati, OH 45229 USA
关键词
Epstein-Barr virus; lymphoproliferative disorder; rituximab;
D O I
10.1016/j.ijporl.2005.04.028
中图分类号
R76 [耳鼻咽喉科学];
学科分类号
100213 ;
摘要
Epstein-Barr virus (EBV) is a ubiquitous viral pathogen in humans that has a unique ability to immortalize B-cells. In immunosuppressed individuals, EBV can produce non-neoplastic lymphoproliferative disorders involving various organs. We describe a case report of EBV-associated lymphoproliferative disorder in an immunocompetent 14-year-old mate. The case provides a description of EBV-associated lymphoproliferation affecting the upper and lower respiratory tract. The massive submucosal. infiltration of B-cells in the lingual tonsils, trachea, and bronchi produced near-complete airway obstruction resulting in tracheotomy. Neither surgical reduction of lingual tonsils nor treatment with steroids was of benefit. An extensive evaluation for immunodeficiency and neoplasia was normal. Treatment with rituximab, an anti-CD20 antibody, resulted in near-complete resolution of the infiltrative process, sufficient to allow decannulation. Rituximab is a treatment option for the rare occurrence of non-neoplastic, EBV-associated, lymphoproliferative disorders. (c) 2005 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:1591 / 1594
页数:4
相关论文
共 11 条
[1]  
DEMETRICK DJ, 1992, CANCER, V70, P519, DOI 10.1002/1097-0142(19920715)70:2&lt
[2]  
519::AID-CNCR2820700224&gt
[3]  
3.0.CO
[4]  
2-4
[5]   Epstein-Barr virus: Induction and control of cell transformation [J].
Dolcetti, R ;
Masucci, MG .
JOURNAL OF CELLULAR PHYSIOLOGY, 2003, 196 (02) :207-218
[6]   Humanized anti-CD20 monoclonal antibody (Rituximab) treatment for post-transplant lymphoproliferative disorder [J].
Ganne, V ;
Siddiqi, N ;
Kamaplath, B ;
Chang, CC ;
Cohen, EP ;
Bresnahan, BA ;
Hariharan, S .
CLINICAL TRANSPLANTATION, 2003, 17 (05) :417-422
[7]   Isolated pleural PTLD after cardiac transplantation [J].
Lamba, M ;
Jabi, M ;
Padmore, R ;
Sengar, DPS ;
Veinot, JP .
CARDIOVASCULAR PATHOLOGY, 2002, 11 (06) :346-350
[8]  
Peter J, 1998, Pediatr Rev, V19, P276, DOI 10.1542/pir.19-8-276
[9]   Posttransplant lymphoproliferative disorder - Incidence, presentation, and response to treatment in lung transplant recipients [J].
Reams, D ;
McAdams, HP ;
Howell, DN ;
Steele, MP ;
Davis, RD ;
Palmer, SM .
CHEST, 2003, 124 (04) :1242-1249
[10]   Anti-CD20 monoclonal antibody (rituximab) treatment for Epstein-Barr virus-associated, B-cell Lymphoproliferative disease in pediatric liver transplant recipients [J].
Serinet, MO ;
Jacquemin, E ;
Habes, D ;
Debray, D ;
Fabre, M ;
Bernard, O .
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2002, 34 (04) :389-393